Search results
14 sty 2021 · BNP and NT-proBNP have been established as a biomarker for heart failure patients presenting dyspnea. But many pitfalls are present for interpreting the BNP value.
17 lut 2020 · Both BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal pro B-type natriuretic peptide) are widely used to aid diagnosis, assess the effect of therapy, and predict outcomes in heart failure and reduced ejection fraction.
BNP measurement has become a routine part of CHF diagnosis (4). It is well known that a high proportion of CHF patients have diabetes mellitus (DM), and the prognosis is worse for coronary heart disease patients who have DM than for those who do not (5, 6).
23 kwi 2023 · BNP and NT-proBNP levels may be affected by specific comorbidities, such as chronic renal failure, type 2 diabetes mellitus, obesity, and acute coronary syndrome (ACS). Levels are higher in patients with renal failure, diabetes, and ACS and lower in patients with obesity. [7]
13 wrz 2022 · We aimed to establish reference ranges for NT-proBNP and explore the determinants of moderately elevated NT-proBNP under the universal definition of heart failure criteria. This is a cross-sectional study.
8 maj 2018 · Circulating B-type natriuretic peptide (BNP) concentrations strongly predict mortality in patients with heart failure (HF). Both cardiac and extracardiac stimuli influence BNP levels, suggesting that BNP might have similar prognostic value in patients without HF.
11 mar 2024 · The diagnostic and prognostic value of measuring plasma BNP, NT-proBNP and mid-regional pro-ANP (MR-proANP) in patients with HF will be presented here.
